Doxorubicin-loaded chitosan/gold nanoparticles enhance anticancer effects and reduce CLMAT3 and ZNRD1-AS1 expression in colorectal cancer cells Authors: Fatemeh Alizadeh, Ali Rajabi, Sina Goharmomayez, Marziyeh Fathi, Reza Safaralizadeh Published: 2026 ABSTRACT BackgroundGlobally, colorectal cancer (CRC) stands as the second most lethal malignancy. Chemotherapeutic drugs have shown some limitations, including systemic toxicity and non-specificity. Nanocarriers such as chitosan/gold nanoparticles (CS/Au NPs) facilitate drug localization at tumor sites, thereby reducing off-target adverse effects.MethodsDoxorubicin-loaded CS/Au NPs were synthesized, and their physicochemical properties were analyzed using Fourier transform infrared (FT-IR) spectroscopy and dynamic light scattering (DLS). HCT116 cells were treated with both free doxorubicin and CS/Au-DOX NPs. In vitro cytotoxic effects were evaluated using the MTT assay. Additionally, apoptosis induction, cell cycle arrest, and cellular uptake assay were examined by flow cytometry. The scratch assay used to evaluate the effect of CS/Au-DOX NPs on the cell migration potential of HCT116, and the expression levels of CLMAT3 and ZNRD1-AS1 were determined by qRT-PCR.ResultsCS/Au-DOX NPs exhibited high encapsulation efficiency (78%) with favorable nanoscale properties, and were markedly more potent than free doxorubicin against HCT116 cells (IC50 0.5 vs. 3 µM). Flow cytometry revealed significant apoptosis induction, G2/M arrest, and enhanced cellular uptake in HCT116 following treatment with CS/Au-DOX NPs. These NPs also reduced the migration potential of CRC cells. In CRC tissues, CLMAT3 and ZNRD1-AS1 were upregulated, with CLMAT3 overexpression associated with lymph node metastasis, while both lncRNAs showed limited diagnostic value. Notably, CS/Au-DOX NPs downregulated CLMAT3 and ZNRD1-AS1 expression in HCT116 cells.ConclusionCS/Au-DOX NPs substantially enhanced the anticancer efficacy of DOX in the HCT116 cell line. Furthermore, CLMAT3 and ZNRD1-AS1 exhibited only limited utility as diagnostic biomarkers in CRC, suggesting that their clinical applicability in early detection may be restricted. Introduction Colorectal cancer (CRC) is among the top causes of cancer fatalities, and the number of cases is rising, with approximately 900,000 deaths reported annually [1, 2]. Conventional cancer therapies, including chemotherapy and radiotherapy, face significant challenges that limit their specificity and efficacy [3, 4]. Nanocarrier-based drug delivery systems (DDS) constitute a promising approach for targeted therapy by utilizing the enhanced permeability and retention (EPR) effect, affording key advantages over conventional chemotherapy methods and attracting increasing attention for cancer treatments [5, 6]. Doxorubicin (DOX), an anthracycline antibiotic, is a cornerstone in chemotherapy regimens due to its broad-spectrum antitumor activity [7]. Two mechanisms by which DOX exerts its effects in cancer cells are: first, by inserting into DNA and interfering with topoisomerase II–dependent repair processes, and second, by inducing oxidative stress that damages cellular membranes, nucleic acids, and proteins. Unfortunately, it can cause many life- threatening adverse side effects such as cardiotoxicity and rapid clearance from the bloodstream, which limits its clinical application [8, 9]. To overcome these challenges, advanced drug delivery systems like extracellular vesicles and nanoparticles (NPs) were designed, such as liposomes, dendrimers, and hydrogels [10–13]. Recent studies have reported that nanogels, a kind of hydrogel, can be an ideal system for the delivery of various chemotherapeutic drugs as they offer excellent biocompatibility, sustained drug release, greater drug-loading potential, and prolong their circulating lifetime [6, 14, 15]. Among the various NPs, gold nanoparticles (AuNPs) have shown significant anticancer potential by inducing programmed cell death across diverse cancer models [16–18]. The positively charged surface of chitosan-coated gold nanoparticles (CS/Au NPs) enhances their electrostatic interaction with the negatively charged cancer cell membrane and demonstrates favorable characteristics, including stabilization and efficient cellular uptake [19–22]. Although notable advances have been made in detection and therapeutic techniques, the prognosis for advanced CRC remains unsatisfactory, mainly due to late-stage diagnosis and tumor recurrence. Thus, it is imperative to identify tumor biomarkers for an early diagnosis of CRC [23, 24]. Long non-coding RNAs (lncRNAs), defined as non-coding transcripts with more than 200 nucleotides, have garnered significant interest as potential biomarkers owing to their tissue-specific expression profiles and regulatory functions in cancer-associated pathways [25]. In parallel, recent evidence underscores the pivotal role of lncRNAs in cancer biology, including driving tumorigenesis, apoptosis, and therapeutic resistance [26, 27]. Colorectal liver metastasis-associated transcript 3 (CLMAT3), located at 5q33.1, is overexpressed in CRC, correlating with liver metastasis and poor patient survival rate [28]. CLMAT3 sustains CRC cell proliferation by suppressing the APC/Cdh1–Skp2–p27^Kip1 axis [29]. Zinc ribbon domain-containing 1 antisense RNA 1 (ZNRD1-AS1) is an oncogenic lncRNA upregulated in multiple cancers, including liver, cervical, and endometrial cancers [30, 31]. ZNRD1-AS1 enhances cell viability, migration, invasion, and tumor growth by activation of the miR-128-3p/BMI1–NF-κB signaling in retinoblastoma [32]. This research aims to investigate the association between ZNRD1-AS1 and CRC due to the lack of information. Although CLMAT3 and ZNRD1-AS1 have been reported to be dysregulated in several cancers and considered potential biomarkers or therapeutic targets, their modulation in response to nanodrug-based treatment remains largely unexplored. Therefore, this study aims to clarify the CRC-specific biological and clinical significance of these two lncRNAs and to address an important gap in the current literature. Although several studies have investigated doxorubicin-loaded chitosan/gold NPs as anticancer systems, the effects of such nanoformulations on oncogenic lncRNAs involved in CRC progression remain unexplored. Our study aims to investigate the therapeutic efficacy of CS/Au-DOX NPs in HCT116 colorectal cancer cells, focusing on their effects on cell viability, apoptosis induction, cell cycle arrest, and migratory potential. Moreover, the study evaluates the expression profiles of CLMAT3 and ZNRD1-AS1 as potential biomarkers in CRC patients and also following treatment, providing novel insights into the molecular mechanisms underlying nanodrug-mediated anticancer activity. We propose that CS/Au-DOX NPs could not only improve the therapeutic efficacy of DOX but also modulate oncogenic lncRNAs involved in CRC progression, including CLMAT3 and ZNRD1-AS1. Materials and methods Sample collection Sixty pairs of tumorous and adjacent non-tumorous tissues (located ≥ 5 cm from the tumor margin) were obtained (Imam Reza hospital, Tabriz, Iran), none of them had received preoperative chemotherapy. The samples were immediately placed into RNase-free vials, rapidly frozen using liquid nitrogen, maintained at − 80 °C until the RNA extraction procedure was performed. Patients were classified according to their age (≥ 56 or < 56 years), tumor site (colon or rectum), gender (male or female), histological subtype (mucinous adenocarcinoma or adenocarcinoma), and TNM stages (I/II or III/IV). Table 2 summarizes the detailed clinical and pathological features of the participants. Prior to participation, written informed consent was acquired from all individuals. All procedures were conducted in accordance with the ethical standards of the institutional research committee and the Declaration of Helsinki. The experimental procedures were approved by the Research Ethics Committee of Tabriz University (approval number IR.TABRIZU.REC.1403.113). Synthesis of CS/Au NPs 100 mg of medium-molecular-weight chitosan (CS; Sigma-Aldrich, USA) was dissolved in 10 mL of 1% (w/v) acetic acid (Merck, Darmstadt, Germany). Subsequently, 250 µL of chloroauric acid (36 mM) (HAuCl4; Alfa Aesar Co. Inc., Ward Hill, USA) was added dropwise, and the solution was stirred at 70 °C for 30 min. The appearance of a red-purple coloration in the solution indicated the formation of CS/Au NPs. Preparation of CS/Au-DOX NPs Doxorubicin-loaded nanoparticles (CS/Au-DOX NPs) were prepared by initially mixing 5 mg of doxorubicin (Acteropharma, Karaj, Iran) with a volume of 1 mL of the prepared CS/Au NPs and stirring for 30 min. The formulation was then stabilized by the gradual dropwise addition of 1 mL TPP solution (Sigma-Aldrich, USA) under continuous stirring using an ionic crosslinking approach, which was maintained for 1 h. The final solution was centrifuged for 10 min at 12,000 rpm. For stabilizing CS/Au NPs, the protocol was started from the addition of TPP. The resulting supernatant was subsequently harvested and examined to determine the concentration of unloaded doxorubicin by UV–Vis spectrophotometry (Cecil BioAquarius CE 7250, England) at 482 nm. Characterization Encapsulation efficiency and Drug loading of DOX to the CS/Au-DOX NPs Encapsulation efficiency (EE%) and drug loading (DL%) percentages were calculated to assess how well the drug was incorporated into the NPs. EE% indicates the efficiency of encapsulation, while DL% is the proportion of drug mass compared to the total mass of the CS/Au-DOX NPs. The amount of free drug was determined by subjecting the supernatant obtained after centrifugation to UV–Vis spectrophotometric analysis at a wavelength of 482 nm. EE% and DL% of CS/Au-DOX NPs were calculated based on the following equations:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned}\:Amount\:of\:drug\:encapsulated=&\:initial\:drug\:concentration\\&-\mathrm{u}\mathrm{n}\mathrm{l}\mathrm{o}\mathrm{a}\mathrm{d}\mathrm{e}\mathrm{d}\:\mathrm{d}\mathrm{r}\mathrm{u}\mathrm{g}\:\mathrm{c}\mathrm{o}\mathrm{n}\mathrm{c}\mathrm{e}\mathrm{n}\mathrm{t}\mathrm{r}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{o}\mathrm{n}\end{aligned}$$\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:EE\%=\frac{Amount\:of\:drug\:encapsulated}{Total\:amount\:of\:drug\:added\:initially}\:\times\:100$$\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:DL\%=\frac{Amount\:of\:drug\:encapsulated}{Total\:weight\:of\:drug-loaded\:nanoparticle}\:\times\:100$$\end{document} Dynamic light scattering (DLS) and zeta potential measurements Nanoparticle size distribution and zeta potential were evaluated by DLS using a Zetasizer Nano ZS instrument (Malvern Instruments, UK), with dispersions prepared at 1 mg/mL. FT-IR analysis of functional groups To verify the successful synthesis of CS/Au-DOX nanoparticles, Fourier transform infrared (FT-IR) spectra were utilized with a Bruker Tensor 27 spectrophotometer (Germany), covering a spectral range of 400–4000 cm⁻¹. The resulting spectra were analyzed using Origin software (v. 2024). Cell lines and culture Human colorectal cancer cells (HCT116) and Human fetal foreskin fibroblasts cell line (HFFF2) were provided by Pasteur Institute (Tehran, Iran). Both cell types were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, USA) characterized by a high glucose concentration, enriched with 10% heat-inactivated fetal bovine serum (FBS; Biosera, France) and 1% penicillin/streptomycin antibiotic (BioIdea, Iran) within a humidified incubator (Memmert, Germany) at a temperature of 37 °C with 5% CO2. In vitro cytotoxic assay In vitro cytotoxicity was assessed by evaluating cell viability following treatment with free DOX, CS/Au-DOX NPs, and CS/Au NPs without DOX (free NPs) using the MTT assay. A total of 1 × 10⁴ cells per well were seeded into 96-well plates and incubated overnight to ensure sufficient cell adhesion and proliferation. Cells were then treated with different concentrations (0–100 µM) following replacement of the culture medium. Treated cells were maintained for 24 to 72 h. Subsequently, each well received 1 mL of 0.5% MTT solution (Sigma-Aldrich, USA), followed by incubation for 3 h. The medium was then removed, and 150 µL of DMSO (Merck, Germany) was added to solubilize the formazan, with gentle shaking for 20 min. Cellular viability was assessed via 570 nm absorbance readings obtained with an ELx808 microplate reader (BioTek Instruments, USA). IC50 values were then calculated using GraphPad Prism 10 software.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:Cell\:viability\:\left(\%\right)\:=\frac{The\:absorbance\:of\:the\:test\:sample}{The\:absorbance\:of\:the\:control\:sample}\:\times\:100$$\end{document} Cellular uptake study Intracellular uptake studies were conducted to assess the cellular internalization of the nanoparticles. To assess cellular internalization of the synthesized CS/Au-DOX NPs, 5 × 10⁵ cells per well were cultured in 6-well plates and incubated to ensure proper adhesion. After 3 h of treatment, the cells were detached with 200 µL of Trypsin-EDTA (Seragen, Iran) and centrifuged at 1300 rpm for 6 min. The cell pellets were then washed 3 times with cold PBS and suspended in 400 µL PBS for fluorescence measurement on a FACSCalibur flow cytometer (Becton Dickinson, USA). The data were studied using the FlowJo 10.10 software. Apoptosis assay Apoptosis induction was determined using the Annexin V-FITC/PI kit (PADZACO, Iran) double- staining method. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{5\:\times\:10}^{5}$$\end{document}cells were seeded and after incubation time, HCT116 and HFFF2 cells were treated with 0 µM (for unstained and double-stained samples), 3 µM and 1 µM of DOX and 0.5 µM of CS/Au-DOX NPs respectively. After a 48-hour incubation period, cells were harvested by treatment with 200 µL of trypsin and then centrifuged at 1300 rpm for 6 min to obtain the pellet. 1 mL of binding buffer (1%) was added to the pellets and centrifuged for 7 min at 500 rpm. The pellets were resuspended in 100 µL of the manufacturer’s buffer. Following the addition of 1 µL of Annexin V-FITC to all experimental groups (except the unstained group), the samples were incubated in the dark for 15 min at a temperature of 25 °C. Next, 1µL of PI was added to each sample (except unstained) and incubated at room temperature for 5 min, in the dark. After staining, 1 mL of cold PBS was added to all samples and centrifuged. At the final step, the harvested cells were gently resuspended in 400 µL cold PBS and subjected to flow cytometric analysis on a FACSCalibur instrument (Becton Dickinson, USA). Data analysis was performed using FlowJo v10.10 software. Cell cycle study Cell cycle distributions were examined by the PI staining method. Briefly, HCT116 and HFFF2 cells were cultured at a density of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{5\:\times\:10}^{5}$$\end{document} per well and treated with 0 µM (as a control group), 3 µM, and 1 µM of free doxorubicin and 0.5 µM of CS/Au-DOX NPs. After 48 h, cells were collected following trypsinization, rinsed with cold PBS, and fixed with ethanol (70%) at − 20 °C. Then, the fixed cells were centrifuged for 10 min at 1500 rpm, and washed again with PBS. Each sample was incubated with 400 µL of propidium iodide (PI; Merck, Germany) (50 µg/mL) with simultaneous 50 µL of RNase A (Thermo Fisher Scientific, USA) treatment (100 µg/mL) for 45 min at 37 °C. Flow cytometric data were processed using FlowJo v10.10 software to determine the percentage of cells in each cell cycle stages (G0/G1, S, and G2/M). Scratch assay Both HCT116 and HFFF2 cells were cultured in a 6-well plate (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{5\:\times\:10}^{5}$$\end{document} cells per well). When the cells reached 90% confluency (After 24 h), the monolayer was scratched by using a p200 pipette tip. Then, the cells were treated with DOX and CS/Au-DOX NPs in concentrations as mentioned before and incubated for 24 and 48 h. After incubation periods, images were taken using an inverted microscope (Nikon, Japan) at various time points, and the width of the scratched region was measured using ImageJ software (version 1.8.0). The percentage of wound closure was quantified using the following equation:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:Wound\:closure\:\left(\%\right)\:=\frac{Wound\:area\:at\:0\:h\:-Wound\:area\:at\:24h/48h}{Wound\:area\:at\:0\:h}\:\times\:100$$\end{document} RNA extraction, cDNA synthesis, and qRT-PCR HCT116 and HFFF2 cells were cultured and incubated overnight. After treatments (as mentioned previously), cells were detached with trypsin and total RNA was isolated using TRIzol reagent (Invitrogen, Massachusetts, USA). RNA concentration and purity were determined using a NanoDrop UV-vis spectrophotometer (Thermo Fisher Scientific, USA), and RNA integrity was confirmed by electrophoresis on a 2% agarose gel. RNAs were reverse transcribed using the Parstous cDNA synthesis kit as described by the manufacturer. Quantitative real-time PCR analysis was conducted to quantify gene expression using a StepOnePlus system (Applied Biosystems). Reactions were prepared in a 20 µL total volume comprising 1 µL of cDNA (diluted 1:100), 0.3 µL of each primer, 10 µL of SYBR Green PCR master mix (Amplicon, Odense, Denmark), and 8.4 µL of double-distilled water. Reaction conditions consisted of an initial 10 min denaturation at 95 °C, 40 cycles of 95 °C for 30 s, 60 °C for 30 s, and a final 5 min extension step at 72 °C. β-actin was used as the housekeeping gene for data normalization. Primer pairs utilized in this study were designed with OLIGO v7 software and are summarized in Table 1. Primer specificity was confirmed by melt curve analysis at the end of each run; all primer sets showed a single sharp peak, indicating no detectable primer-dimer formation or nonspecific products. Primer amplification efficiency was determined from standard curves generated using serial dilutions of cDNA, according to the equation \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:E={[10}^{-(1/slope)}-1]\:\times\:100$$\end{document}. All primer pairs exhibited acceptable efficiencies (between 90% and 110%). The \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:{2}^{-\varDelta\:CT}\:$$\end{document}method was used to determine relative target gene expression levels, according to the formula below:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\varDelta\:\mathrm{C}\mathrm{T}=\:{\mathrm{C}\mathrm{T}}_{\mathrm{t}\mathrm{a}\mathrm{r}\mathrm{g}\mathrm{e}\mathrm{t}}-\:{\:\mathrm{C}\mathrm{T}}_{\mathrm{r}\mathrm{e}\mathrm{f}\mathrm{e}\mathrm{r}\mathrm{e}\mathrm{n}\mathrm{c}\mathrm{e}}$$\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\mathrm{E}\mathrm{x}\mathrm{p}\mathrm{r}\mathrm{e}\mathrm{s}\mathrm{s}\mathrm{i}\mathrm{o}\mathrm{n}\:\mathrm{R}\mathrm{a}\mathrm{t}\mathrm{i}\mathrm{o}=\:\:{2}^{-\varDelta\:\mathrm{C}\mathrm{T}}$$\end{document} Table 1The sequence of primers used for qRT- PCRGenePrimerTypePrimer sequenceProductSizeCLMAT3ForwardReverse5’-CCATGTGTTGCAGAGGGGAT-3’5’-AGGACGGGTTTTCAGCAGTT-3’189ZNRD1-AS1ForwardReverse5’-CAAAATTGGAACGCAGTCGC-3’5’-GGACCCAAGGAACGCTAGAA-3’187β -actinForwardReverse5’-AGAGCTACGAGCTGCCTGAC-3’5’-AGCACTGTGTTGGCGTACAG-3’184 Table 1The sequence of primers used for qRT- PCRGenePrimerTypePrimer sequenceProductSizeCLMAT3ForwardReverse5’-CCATGTGTTGCAGAGGGGAT-3’5’-AGGACGGGTTTTCAGCAGTT-3’189ZNRD1-AS1ForwardReverse5’-CAAAATTGGAACGCAGTCGC-3’5’-GGACCCAAGGAACGCTAGAA-3’187β -actinForwardReverse5’-AGAGCTACGAGCTGCCTGAC-3’5’-AGCACTGTGTTGGCGTACAG-3’184 The sequence of primers used for qRT- PCR Forward Reverse 5’-CCATGTGTTGCAGAGGGGAT-3’ 5’-AGGACGGGTTTTCAGCAGTT-3’ Forward Reverse 5’-CAAAATTGGAACGCAGTCGC-3’ 5’-GGACCCAAGGAACGCTAGAA-3’ Forward Reverse 5’-AGAGCTACGAGCTGCCTGAC-3’ 5’-AGCACTGTGTTGGCGTACAG-3’ Statistical analysis All in vitro experiments were performed in at least three independent biological replicates, and technical triplicates were included for each condition to improve reproducibility. The clinical sample size was determined by the availability of eligible patients during the study period, as this work was designed as an exploratory translational study. The collected data were analyzed with GraphPad Prism 10.3 and SPSS 24 software. Flow cytometry results were processed and analyzed with FlowJo software version 10.10. Group differences were analyzed using both the t-test and one-way analysis of variance (ANOVA). All results are presented as mean ± SD, with p < 0.05 indicating statistical significance. Results CLMAT3 and ZNRD1-AS1 expression pattern in CRC CLMAT3 and ZNRD1-AS1 expression levels were determined in 60 pairs of tumor and non-tumorous tissues by qRT-PCR. As illustrated in Fig. 1a-b, the results revealed that the CLMAT3 and ZNRD1-AS1 gene expressions were notably increased in tumor tissues as compared to adjacent healthy tissues (with P = 0.0012 and P = 0.014). The results suggest that ZNRD1-AS1 and CLMAT3 exhibit an oncogenic pattern in colorectal cancer. Fig. 1Upregulation of (a) CLMAT3 and (b) ZNRD1-AS1 in CRC tissues compared with adjacent normal tissues. *p < 0.05, **p < 0.01. ROC curve analysis for the expression of (c) CLMAT3 (AUC = 0.6615; specificity = 56.67%; sensitivity = 71.67%), and (d) ZNRD1-AS1 (A UC = 0.6432; specificity = 63.83%; sensitivity = 62%) Upregulation of (a) CLMAT3 and (b) ZNRD1-AS1 in CRC tissues compared with adjacent normal tissues. *p < 0.05, **p < 0.01. ROC curve analysis for the expression of (c) CLMAT3 (AUC = 0.6615; specificity = 56.67%; sensitivity = 71.67%), and (d) ZNRD1-AS1 (A UC = 0.6432; specificity = 63.83%; sensitivity = 62%) Biomarker potency of CLMAT3 and ZNRD1-AS1 ROC curve analysis was performed to assess the diagnostic value of ZNRD1-AS1 and CLMAT3 expression (Fig. 1c-d). At a cutoff value of < 0.05311, CLMAT3 exhibited a sensitivity of 71.67% and a specificity of 56.67%, whereas ZNRD1-AS1 showed a sensitivity of 62% and a specificity of 63.83% at a cutoff value of > 0.02013. These results demonstrated that CLMAT3 (with AUC = 0.6615, and P = 0.002) and ZNRD1-AS1 (with AUC = 0.6432, and P = 0.015) exhibit weak to moderate diagnostic value in colorectal cancer. The correlation of CLMAT3 and ZNRD1-AS1 upregulations and clinicopathological parameters in CRC The association between CLMAT3 and ZNRD1-AS1 upregulation and various clinicopathological characteristics of CRC patients, including age, tumor site, gender, lymphatic metastasis, histological type, TNM stage, tumor differentiation, and H. pylori infection, was examined (Table 2). The obtained findings indicated a correlation between CLMAT3 and lymph node metastasis (P = 0.04). In contrast, no significant association was observed between CLMAT3 and ZNRD1-AS1 with other clinicopathological features. Table 2Correlation between CLMAT3 and ZNRD1-AS1 expression levels and clinicopathological features of CRC casesClinicopathologicFeaturesFrequency (%)Mean expression of CLMAT3 in tumorMean expression of CLMAT3 innon-tumorCorrelation with CLMAT3 expression (P-value)Mean expression of ZNRD1-AS1 in tumorMean expression of ZNRD1-AS1 innon-tumorCorrelation with ZNRD1-AS1 expression(P-value)Age< 56\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\ge\:$$\end{document}5646.6653.330.0918\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08520.1046\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11130.0901\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10550.0681\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07420.740.0459\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04330.0781\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14640.0481\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05840.0420\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07580.68GenderMaleFemale55450.0705\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07090.1330\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11840.0733\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09400.0846\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08650.070.0615\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07540.0605\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14480.0366\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04460.0549\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08800.95Tumor siteRectumColon50500.1146\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11400.0860\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08230.0828\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09350.0739\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08790.570.0502\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06030.0760\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14550.0511\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08720.0386\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04060.89Tumor histologyMucinous adenocarcinomaAdenocarcinoma40600.1005\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08920.0973\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10690.0782\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10600.0784\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07920.420.0762\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15870.0543\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06300.0408\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05190.0475\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07720.52Tumor differentiationWell/moderatePoor56.6643.330.1071\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10020.0875\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09910.0805\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09120.0756\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09030.070.0614\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.13170.0653\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07940.0392\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04730.0522\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08810.24TNM stageI/IIIII/IV51.6648.330.0750\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07640.1238\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11530.0701\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08890.0872\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09210.120.0442\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04060.0832\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15320.0369\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04820.0533\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08380.54Lymph metastasisYesNo36.6663.330.0831\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09530.1254\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10280.0617\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06090.0880\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1031 0.04 0.0349\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.03490.0794\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.13570.0571\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09440.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04550.64H.pylori infectionYesNo40600.0968\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09200.0998\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10530.0924\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10490.0690\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07880.780.0761\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15760.0544\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06490.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05000.0495\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07780.87 Table 2Correlation between CLMAT3 and ZNRD1-AS1 expression levels and clinicopathological features of CRC casesClinicopathologicFeaturesFrequency (%)Mean expression of CLMAT3 in tumorMean expression of CLMAT3 innon-tumorCorrelation with CLMAT3 expression (P-value)Mean expression of ZNRD1-AS1 in tumorMean expression of ZNRD1-AS1 innon-tumorCorrelation with ZNRD1-AS1 expression(P-value)Age< 56\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\ge\:$$\end{document}5646.6653.330.0918\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08520.1046\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11130.0901\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10550.0681\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07420.740.0459\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04330.0781\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14640.0481\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05840.0420\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07580.68GenderMaleFemale55450.0705\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07090.1330\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11840.0733\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09400.0846\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08650.070.0615\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07540.0605\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14480.0366\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04460.0549\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08800.95Tumor siteRectumColon50500.1146\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11400.0860\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08230.0828\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09350.0739\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08790.570.0502\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06030.0760\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.14550.0511\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08720.0386\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04060.89Tumor histologyMucinous adenocarcinomaAdenocarcinoma40600.1005\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08920.0973\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10690.0782\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10600.0784\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07920.420.0762\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15870.0543\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06300.0408\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05190.0475\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07720.52Tumor differentiationWell/moderatePoor56.6643.330.1071\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10020.0875\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09910.0805\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09120.0756\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09030.070.0614\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.13170.0653\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07940.0392\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04730.0522\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08810.24TNM stageI/IIIII/IV51.6648.330.0750\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07640.1238\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.11530.0701\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08890.0872\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09210.120.0442\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04060.0832\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15320.0369\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04820.0533\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.08380.54Lymph metastasisYesNo36.6663.330.0831\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09530.1254\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10280.0617\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06090.0880\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1031 0.04 0.0349\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.03490.0794\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.13570.0571\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09440.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.04550.64H.pylori infectionYesNo40600.0968\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.09200.0998\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10530.0924\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.10490.0690\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07880.780.0761\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.15760.0544\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.06490.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.05000.0495\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.07780.87 Correlation between CLMAT3 and ZNRD1-AS1 expression levels and clinicopathological features of CRC cases Age < 56 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\ge\:$$\end{document}56 46.66 53.33 0.0918\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0852 0.1046\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1113 0.0901\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1055 0.0681\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0742 0.0459\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0433 0.0781\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1464 0.0481\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0584 0.0420\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0758 Gender Male Female 55 45 0.0705\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0709 0.1330\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1184 0.0733\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0940 0.0846\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0865 0.0615\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0754 0.0605\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1448 0.0366\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0446 0.0549\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0880 Tumor site Rectum Colon 50 50 0.1146\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1140 0.0860\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0823 0.0828\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0935 0.0739\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0879 0.0502\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0603 0.0760\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1455 0.0511\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0872 0.0386\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0406 Tumor histology Mucinous adenocarcinoma Adenocarcinoma 40 60 0.1005\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0892 0.0973\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1069 0.0782\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1060 0.0784\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0792 0.0762\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1587 0.0543\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0630 0.0408\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0519 0.0475\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0772 Tumor differentiation Well/moderate Poor 56.66 43.33 0.1071\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1002 0.0875\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0991 0.0805\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0912 0.0756\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0903 0.0614\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1317 0.0653\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0794 0.0392\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0473 0.0522\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0881 TNM stage I/II III/IV 51.66 48.33 0.0750\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0764 0.1238\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1153 0.0701\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0889 0.0872\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0921 0.0442\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0406 0.0832\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1532 0.0369\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0482 0.0533\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0838 Lymph metastasis Yes No 36.66 63.33 0.0831\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0953 0.1254\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1028 0.0617\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0609 0.0880\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1031 0.0349\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0349 0.0794\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1357 0.0571\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0944 0.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0455 H.pylori infection Yes No 40 60 0.0968\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0920 0.0998\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1053 0.0924\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1049 0.0690\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0788 0.0761\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.1576 0.0544\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0649 0.0378\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0500 0.0495\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document}0.0778 Characterization of CS/Au-DOX NPs Encapsulation efficiency and Drug loading study The drug-loaded nanoparticles exhibited an encapsulation efficiency (EE%) of 78% and a drug loading (DL%) of 19.5%. These results demonstrate the effectiveness of the encapsulation method used for the preparation of CS/Au-DOX NPs. DLS and FT-IR Successful synthesis of CS/Au-DOX NPs was confirmed through physicochemical characterization techniques. As shown in Fig. 2a, DLS analysis revealed a mean hydrodynamic size of 166.9 nm, which is a suitable size for NPs. Additionally, the surface charge and colloidal stability of them were evaluated via zeta potential measurement, which revealed + 30 mV, indicating high colloidal stability in aqueous media. Due to the negatively charged cell membrane surface, positively charged NPs facilitate efficient cellular uptake and promote strong attachment of CS/Au-DOX NPs to the HCT116 cancer cells. FTIR can be used to assess the functional groups of NPs. Figure 2b illustrates the FTIR spectrum results. The FTIR spectra of both CS/Au NPs and CS/Au-DOX NPs had similar characteristic peaks, since they basically had the same functional groups. Both samples exhibit characteristic absorption bands of chitosan, including the broad O-H stretching vibration around 3400 cm⁻¹, C-H stretching peaks near 2900 cm⁻¹, and C-O-C at 1000–1100 cm⁻¹ [20–22, 33]. Intensified absorption bands of CS/Au-DOX NPs in the 1000–1700 cm⁻¹, attributable to DOX aromatic and carbonyl functionalities, indicate successful DOX loading onto the CS/Au NPs [34]. Additionally, a peak at 3550 cm⁻¹, corresponding to O–H/N–H stretching of DOX and its hydrogen-bonding interactions with chitosan, confirms successful DOX loading. The peak at 1068 cm⁻¹ corresponds to the P = O bond of TPP, confirming the stabilized formation of our nanoparticles [20]. In the drug-loaded CS/Au-DOX NPs, these characteristic peaks are retained with slight shifts and changes in intensity, indicating successful encapsulation of doxorubicin without significant alteration of the chitosan matrix, which can be ascribed to the structural stability of CS/Au NPs after successful encapsulation of DOX. Fig. 2Characteristics of NPs. a Size distribution of CS/Au-DOX NPs measured by DLS; b FT-IR spectrum of CS/Au and CS/Au-DOX NPs in the range of 400–4000 cm⁻¹ Characteristics of NPs. a Size distribution of CS/Au-DOX NPs measured by DLS; b FT-IR spectrum of CS/Au and CS/Au-DOX NPs in the range of 400–4000 cm⁻¹ Cell viability The in vitro cytotoxicity of free CS/Au NPs, CS/Au-DOX NPs, and free DOX on HCT116 and HFFF2 cell lines was evaluated with the MTT assay. This test evaluates cell viability by measuring the reduction of MTT to formazan catalyzed by succinate dehydrogenase in viable cells. Free CS/Au NPs exhibited negligible cytotoxicity: HCT116 cells maintained ≥ 95% viability across all tested concentrations, and HFFF2 cells maintained ≥ 93% viability. These results demonstrate that free CS/Au NPs had no cytotoxic effect on both cell lines, highlighting their biocompatibility. CS/Au-DOX NPs exhibited nearly similar cytotoxicity to free DOX in normal HFFF2 cells, while the cytotoxicity of CS/Au-DOX NPs against HCT116 cells was dramatically higher (Fig. 3). The half maximal inhibitory concentration (IC50) of DOX and CS/Au-DOX NPs on the HCT116 cell line was 3 µM and 0.5 µM, respectively. The measured IC50 values of free DOX and CS/Au-DOX NPs on HFFF2 cells were 1 µM and 0.5 µM, respectively. Although some toxicity was evident in HFFF2 cells, the overall response was less intense than in HCT116 cells, indicating an improved, but not absolute, therapeutic window for DOX. Overall, the results demonstrate that the encapsulation of DOX in CS/Au NPs enhances the anticancer activity by decreasing the effective concentration to inhibit the growth of the HCT116 cell line. The IC50 value of CS/Au-DOX nanoparticles was significantly lower than that of free DOX in HCT116 cells, which demonstrates the increased potency of the encapsulated formulation. Fig. 3Cytotoxicity of DOX, CS/Au NPs, and CS/Au-DOX NPs in (a) HCT116 and (b) HFFF2 cells. CS/Au NPs had no cytotoxic effect on both cell lines, highlighting the biocompatibility of these NPs. CS/Au-DOX NPs induced higher cytotoxicity in HCT116 cells than free DOX at all treated concentrations, exhibiting dose- and time-dependent effects. In contrast, CS/Au-DOX NPs showed no significant cytotoxicity in HFFF2 cells compared to free DOX Cytotoxicity of DOX, CS/Au NPs, and CS/Au-DOX NPs in (a) HCT116 and (b) HFFF2 cells. CS/Au NPs had no cytotoxic effect on both cell lines, highlighting the biocompatibility of these NPs. CS/Au-DOX NPs induced higher cytotoxicity in HCT116 cells than free DOX at all treated concentrations, exhibiting dose- and time-dependent effects. In contrast, CS/Au-DOX NPs showed no significant cytotoxicity in HFFF2 cells compared to free DOX Cellular uptake Flow cytometric analysis of cellular uptake indicated that CS/Au-DOX NPs significantly enhance DOX uptake in both cell lines, especially toward HCT116 cancer cells (Fig. 4). This could be a result of the greater tendency of positively charged nanoparticles to interact with the negatively charged cancer cell membrane. Fig. 4The cellular uptake of CS/Au-DOX NPs by (a) HCT116 and (b) HFFF2 cells was assessed by flow cytometry after a 3 h incubation period The cellular uptake of CS/Au-DOX NPs by (a) HCT116 and (b) HFFF2 cells was assessed by flow cytometry after a 3 h incubation period Apoptosis Apoptosis analysis of the HCT116 and HFFF2 cells, stained by Annexin V and PI, indicated that the total apoptosis rates were 10.9% and 14.25% in HFFF2, and 27.85% and 46% in HCT116 treated with DOX and CS/Au-DOX NPs, respectively. The significantly higher apoptosis induction by CS/Au-DOX NPs compared to free DOX in HCT116 cancer cells (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:p\:\le\:\:0.0001$$\end{document}), with a modest rise in necrosis (DOX = 5.08%, CS/Au-DOX NPs = 8.19%), demonstrates the enhanced effectiveness of the nanoparticle formulation. This increase in apoptosis induction can be associated with more cellular drug uptake by NPs. Treatment with free DOX in the HFFF2 cell line resulted in 4.0% necrosis and 85.1% live cells. In contrast, treatment with CS/Au-DOX NPs showed 1.27% necrosis and 84.5% live cells. These results demonstrate a reduction in necrosis in cells treated with the CS/Au-DOX NPs, while maintaining a high viability of over 84% in both treatments, and indicate the selective cytotoxicity and biocompatibility of these, which is crucial for minimizing side effects in normal tissues during drug delivery. All results are summarized in Fig. 5. The data suggest that CS/Au-DOX NPs can more effectively modulate apoptotic pathways in CRC cells. Fig. 5a HCT116 control group, b HCT116 free DOX-treated group, c HCT116 CS/Au-DOX NPs treated group, d HFFF2 Control group, e HFFF2 free DOX-treated group, and (f) HFFF2 CS/Au-DOX NPs treated group at IC50 concentrations showing percentages of viable, total apoptotic, and necrotic cells; g The bar charts illustrate the mean percentage of apoptotic cells induced in HCT116 cells; h The bar charts illustrate the mean percentage of apoptotic cells induced in HFFF2 cells ****p < 0.0001 a HCT116 control group, b HCT116 free DOX-treated group, c HCT116 CS/Au-DOX NPs treated group, d HFFF2 Control group, e HFFF2 free DOX-treated group, and (f) HFFF2 CS/Au-DOX NPs treated group at IC50 concentrations showing percentages of viable, total apoptotic, and necrotic cells; g The bar charts illustrate the mean percentage of apoptotic cells induced in HCT116 cells; h The bar charts illustrate the mean percentage of apoptotic cells induced in HFFF2 cells ****p < 0.0001 Cell cycle The effects of free DOX and CS/Au-DOX NPs treatment on the distribution of HCT116 and HFFF2 cells across cell cycle phases were evaluated using flow cytometry. Treatment with CS/Au-DOX NPs exerts the effects by cell cycle arrest in G2/M in HCT116 (Fig. 6). Treatment of HCT116 cells with IC50 values of DOX (3 µM) and CS/Au-DOX NPs (0.5 µM) markedly increased the cells’ distribution in the G2/M phase, from 15.6% (control group) to 22.5% (DOX-treated group) and 60.7% (CS/Au-DOX-treated group) (P = 0.0004 and P < 0.0001, respectively). While treatment of HFFF2 cells with IC50 doses of doxorubicin (1 µM) and CS/Au-DOX NPs (0.5 µM) resulted in no significant differences in cell cycle distribution. Treatment with free DOX and CS/Au-DOX NPs resulted in a modest elevation of G2/M phase cells, 15.9% in the control group to 26.0% and 18.4%, respectively. Clearly, CS/Au-DOX NPs induced a smaller increase in the G2/M phase compared to free DOX in HFFF2 normal cells (Fig. 6). Fig. 6Cell cycle distribution of cells assessed by flow cytometry after 48 h treatment with IC50 concentrations of (a) HCT116 Control group, b HCT116 free DOX-treated group, c HCT116 CS/Au-DOX NPs treated group, d HFFF2 Control group, e HFFF2 free DOX-treated group, and (f) HFFF2 CS/Au-DOX NPs treated group. HCT116 cells treated with CS/Au-DOX NPs showed a significant increase in the G2/M phase (p < 0.0001) while, treatment of HFFF2 cells with CS/Au-DOX NPs resulted in no significant differences in cell cycle distribution; g The distribution of HCT116 cells among the various cell cycle phases are shown in bar charts; h The distribution of HFFF2 cells among the various cell cycle phases are shown in bar charts. ***p < 0.001, ****p < 0.0001 Cell cycle distribution of cells assessed by flow cytometry after 48 h treatment with IC50 concentrations of (a) HCT116 Control group, b HCT116 free DOX-treated group, c HCT116 CS/Au-DOX NPs treated group, d HFFF2 Control group, e HFFF2 free DOX-treated group, and (f) HFFF2 CS/Au-DOX NPs treated group. HCT116 cells treated with CS/Au-DOX NPs showed a significant increase in the G2/M phase (p < 0.0001) while, treatment of HFFF2 cells with CS/Au-DOX NPs resulted in no significant differences in cell cycle distribution; g The distribution of HCT116 cells among the various cell cycle phases are shown in bar charts; h The distribution of HFFF2 cells among the various cell cycle phases are shown in bar charts. ***p < 0.001, ****p < 0.0001 Scratch The scratch test was conducted to assess the effects of free DOX and CS/Au-DOX NPs treatment on cell migration. Representative images were acquired at 0, 24, and 48 h to evaluate wound closure in the treated and control groups. At 0 h, all groups exhibited a similar initial scratch width with clear void areas. After 24 and 48 h, partial closure of the scratch area was observed in all treatment groups; however, the CS/Au-DOX NPs group showed a reduced migration rate compared to free DOX and control (untreated) groups. As shown in Fig. 7a and b, in 48 h, the CS/Au-DOX NPs treated HCT116 cells had the slowest migration with a significantly larger scratch area still open, and the DOX group showed moderate closure, whereas the control group nearly achieved complete scratch closure. Quantitative image analysis confirmed these observations, highlighting a statistically significant decrease (p < 0.0001) in scratch closure rate for the CS/Au-DOX NPs group compared to DOX and control at both 24 h and 48 h time points. Similarly, this assay was performed on HFFF2 human foreskin fibroblasts under the same conditions (Fig. 7c and d). At 0 h, a uniform scratch width was observed in all treatment groups. By 48 h, the scratch area in the control group had almost completely closed, while the inhibitory effects of both treated groups on cell migration were less pronounced and exhibited only slight differences. These results demonstrate that CS/Au-DOX NPs significantly decreased the migration potential of HCT116 colorectal cancer cells compared with DOX treatment alone. Fig. 7a Effects of free DOX and CS/Au-DOX NPs on HCT116 cell migration after 24 and 48 h. Scratched areas were measured by ImageJ software. CS/Au-DOX NPs group showed reduced migration rate compare to free DOX and control (untreated) groups. In 48 h, the CS/Au-DOX NPs treated HCT116 cells had the slowest migration with a significantly larger scratch area still open; b The bar charts represent the percentage of HCT116 cells migration rate. c Effects of free DOX and CS/Au-DOX NPs on HFFF2 cell migration after 24 and 48 h. Scratched areas were measured by ImageJ software. The inhibitory effects of both treated groups on HFFF2 cells exhibited only slight differences; d The bar charts represent the percentage of HFFF2 cells’ migration rate. **p < 0.01, ***p < 0.001, ****p < 0.0001 a Effects of free DOX and CS/Au-DOX NPs on HCT116 cell migration after 24 and 48 h. Scratched areas were measured by ImageJ software. CS/Au-DOX NPs group showed reduced migration rate compare to free DOX and control (untreated) groups. In 48 h, the CS/Au-DOX NPs treated HCT116 cells had the slowest migration with a significantly larger scratch area still open; b The bar charts represent the percentage of HCT116 cells migration rate. c Effects of free DOX and CS/Au-DOX NPs on HFFF2 cell migration after 24 and 48 h. Scratched areas were measured by ImageJ software. The inhibitory effects of both treated groups on HFFF2 cells exhibited only slight differences; d The bar charts represent the percentage of HFFF2 cells’ migration rate. **p < 0.01, ***p < 0.001, ****p < 0.0001 qRT-PCR To assess the effects of CS/Au-DOX NPs and free DOX on CLMAT3 and ZNRD1-AS1 expression in HCT116 and HFFF2 cells, their expression levels were quantified by qRT-PCR. CS/Au-DOX NPs treatment markedly reduced the expression level of ZNRD1-AS1 and CLMAT3 in HCT116 compared with the untreated group (P < 0.0001) (Fig. 8). Furthermore, treatment with CS/Au-DOX NPs induced greater downregulation than DOX alone (P < 0.0001). In contrast, CS/Au-DOX NPs treatment slightly reduced the expression of ZNRD1-AS1 (P = 0.0172) compared to free DOX, and no statistically significant changes in CLMAT3 expression were detected between the CS/Au-DOX NPs treatment and DOX groups in HFFF2 cells. All results indicate that CS/Au-DOX NPs may improve tumor-specific therapeutic activity of doxorubicin. Fig. 8Expression of (a) CLMAT3 and (b) ZNRD1-AS1 lncRNAs in HCT116 and HFFF2 cells following 48 h exposure to DOX and CS/Au-DOX NPs. In HCT116 cells, CS/Au-DOX NPs significantly reduced the expression of both CLMAT3 and ZNRD1-AS1 compared to free DOX. Conversely, no notable differences were shown between treatment groups in HFFF2 cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Expression of (a) CLMAT3 and (b) ZNRD1-AS1 lncRNAs in HCT116 and HFFF2 cells following 48 h exposure to DOX and CS/Au-DOX NPs. In HCT116 cells, CS/Au-DOX NPs significantly reduced the expression of both CLMAT3 and ZNRD1-AS1 compared to free DOX. Conversely, no notable differences were shown between treatment groups in HFFF2 cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Discussion CRC represents the second most common lethal malignancy worldwide [1, 35]. Although significant advances have been achieved in therapeutic strategies, the prognosis of advanced CRC remains poor, mainly due to late diagnosis and tumor metastasis [23, 36]. Our study examined the expression patterns of CLMAT3 and ZNRD1-AS1 in CRC tissues and marginal tissues. The results revealed significant upregulation of CLMAT3 and ZNRD1-AS1 in CRC tissues compared to control samples and correlation of CLMAT3 expression with lymph node metastasis (p = 0.04) in CRC patients. ROC curve analysis indicated that both CLMAT3 (AUC = 0.6615) and ZNRD1-AS1 (AUC = 0.6432) exhibited weak-to-moderate diagnostic performance in differentiating CRC tissues from adjacent normal tissues. Similar studies indicated that, among MEG3, HOXA11-AS, DANCR, SLCO4A1-AS1, and SPINT1-AS1 lncRNAs, SPINT1-AS1 and SLCO4A1-AS1 exhibited the best values in ROC curve analysis [25]. Based on Yu et al., SLCO4A1-AS1 displayed high diagnostic value (AUC = 0.924), indicating its utility as a diagnostic biomarker for CRC. Expression level of the SLCO4A1-AS1 gene was significantly upregulated in tumor samples and correlated with lymph node involvement and higher TNM stage [37]. Li et al. confirmed that SPINT1-AS1 showed considerable diagnostic value (AUC = 0.865), and the expression level was correlated with adverse clinicopathological features, including lymph node and distant metastasis in CRC [38]. Ye et al. demonstrated that high CLMAT3 expression correlated with both lymph node and liver metastasis (P = 0.03, P = 0.009), which are consistent with our results [28]. A growing number of studies have validated the oncogenic function of ZNRD1-AS1 in multiple cancer types. According to Ye et al., elevated ZNRD1-AS1 expression in gastric cancer correlated with lymph node metastasis and distal dissemination. Functional assays demonstrated that ZNRD1-AS1 enhances cell proliferation through its role as a ceRNA for miR-9-5p. Knockdown of ZNRD1-AS1 markedly reduces tumor growth and pulmonary metastasis, supporting its potential as a diagnostic marker in gastric malignancies [39]. Bladder cancer studies by Gao et al. corroborated an oncogenic role for ZNRD1-AS1, demonstrated elevated expression in tumor tissues and cell lines. Knockdown of ZNRD1-AS1 suppresses tumor progression by regulating the miR-194/ZEB1 axis [40]. Although both CLMAT3 and ZNRD1-AS1 were upregulated in CRC tissues, their diagnostic utility appears limited compared with previously mentioned CRC-related lncRNAs with higher AUC values, and may be more useful as complementary biomarkers. Targeted drug delivery restricts the treatment of CRC. Systemic toxicity is the major limitation of conventional chemotherapy drugs, which can reduce their specificity and efficacy [41, 42]. DOX is a chemotherapeutic drug that damages cancer cells through DNA intercalation, t ROS generation, and topoisomerase II inhibition. However, cardiotoxicity, myelosuppression, immunogenicity, and short circulation time in the bloodstream limit its clinical application [8, 43]. Nanocarrier-based drug delivery systems (DDS) present a promising approach, affording key advantages over conventional chemotherapy methods. Due to the EPR effect, NPs can selectively localize within solid tumor tissues, which enhances tumor-specific drug delivery, resulting in higher drug concentrations at the tumor site while reducing off-target toxicity to healthy tissues [42, 44]. Chitosan (CS) is a biologically active polymer widely used in medical fields owing to its low toxicity and biodegradability [45]. Among the various classes of nanoparticles, chitosan-coated gold nanoparticles (CS/AuNPs) have been demonstrated to have favorable characteristics. Compared with liposomes, which often have stability and premature drug release limitations, CS/Au-DOX NPs combine chitosan’s biocompatibility with the stability of gold NP. Unlike PLGA, with complex synthesis and slower drug release, chitosan-based NPs are simpler to prepare, more environmentally friendly, and can provide pH-responsive release profiles. While inorganic NPs such as silica or iron oxide provide unique imaging and magnetic properties, they raise concerns about long-term biotoxicity and clearance. CS/Au NPs, by contrast, exhibit low cytotoxicity and tunable surface chemistry. Compared to dendrimers, with high cationic charge and toxicity, CS/Au NPs are less toxic [19, 21, 44, 46, 47]. In the present study, CS/Au-DOX NPs were prepared using a cross-link technique by the addition of TPP solution, resulting in a hydrodynamic size of 166.9 nm, a surface charge of + 30 mV, and a higher rate of cellular uptake compared to free DOX. Notably, nanoparticle size plays a critical role in cellular internalization [48]. Specifically, nanodrugs within the size range of 100 to 200 nm show higher uptake efficiency [3]. Nanoparticles with zeta potential values exceeding ± 30 mV are regarded as physical stability and prevent aggregation [49]. Here, we evaluated CS/Au-DOX NPs effect on the HCT116 and HFFF2 cell lines. Based on MTT results, our findings are consistent with previous reports demonstrating the induction of concentration-dependent cell death by DOX in cancer cells [50]. We extend previous findings by demonstrating that DOX encapsulated within CS/Au NPs show a greater cytotoxic effect in HCT116 cells with a 6-fold reduction in IC50 value (IC50 of DOX = 3 µM, IC50 of CS/Au-DOX = 0.5 µM), underscoring its potential as an effective drug delivery platform for CRC. Gounden et al. reported that CS-Au-5-FU demonstrated strong cytotoxic activity against MCF-7 cells, with a significantly lower IC₅₀ for CS-Au-5-FU formulation compared to 5-FU, with reduced cytotoxicity in non-cancerous HEK293 cells, indicating enhanced therapeutic efficacy [46]. Similarly, MTT assays demonstrated that DOX-loaded nanogels exhibited enhanced cellular permeability in A549, HeLa, and MCF-7 cell lines, leading to greater intracellular accumulation of DOX compared with the free drug [51]. We further confirmed the anti-proliferative effect of CS/Au-DOX NPs by flow cytometry. The results show that CS/Au-DOX NPs effectively induce apoptosis in HCT116 cells compared to both control and free DOX groups. The elevated apoptotic rate observed in treated cells aligns with the G2/M phase arrest results, indicating that the treatment may trigger apoptotic pathways following cell cycle blockade. Previous reports have also indicated that treatment with DOX@NOCC-g NGs in MCF-7 causes DNA damage and cell cycle arrest [52]. According to Rahmani et al., DOX-loaded βCD-g-PMA-co-PLGA micelles significantly induce apoptosis, and G2/M phase arrest of 67% was observed in the MDA-MB-231 cell line [53]. Moreover, based on the study by Jalilzadeh et al. on HT-29 cells, the AUR loaded NPS treated groups showed enhanced apoptotic induction and ratio of cells in the sub-G1 compared to free AUR [54]. Flow cytometry results of Zhang et al. study highlight a notable apoptosis rate increase in HeLa cells treated with CS/Au-DOX NPs versus free DOX, indicative of improved therapeutic efficacy [55]. We further assessed the effect of DOX-loaded CS/AU NPs in inhibiting HCT116 cancer cell migration and metastasis. The scratch assay confirmed the anti-migration effect of CS/Au-DOX NPs on the HCT116 cancer cells compared to the control and DOX groups, while there is no significant effect on the migration ability of HFFF2 cells between the CS/Au-DOX NPs and the DOX-treated groups. These results are in line with the study by Seifi-Najmi et al., reported that SiRNA/DOX-loaded chitosan-based NPs prevent cell migration and invasion in the A549 lung cancer cell line [56]. Although CS/Au NPs have been investigated in cancer therapy, their impact on lncRNA expression remains largely unexplored. While previous research has focused on the cytotoxic and physicochemical features of these NPs, our findings extend this understanding by revealing their effects on the expression of CLMAT3 and ZNRD1-AS1 lncRNAs. Our qRT-PCR results showed a notable decrease in expression levels of ZNRD1-AS1 and CLMAT3 in HCT116 cells following treatment with CS/Au-DOX NPs. Therefore, while our clinical data demonstrated that these specific lncRNAs have limited value as diagnostic biomarkers, their significant downregulation following CS/Au-DOX NP therapy underscores their strong therapeutic potential. The G2/M cell cycle arrest suggests that CS/Au-DOX NPs can activate the DNA damage checkpoint in HCT116 cells, through topoisomerase II inhibition and sustained ROS generation. This activates the ATM/ATR–Chk1/Chk2 pathway, halting the cell cycle at the G2/M phase by inhibiting the Cyclin B1/Cdc2 complex. This DNA damage response likely drives the observed lncRNA downregulation through two interconnected mechanisms: (i) ROS directly alters transcription of stress-responsive lncRNAs, and (ii) ROS-activated NF-κB signaling binds lncRNA (such as HOTAIR and MIR31HG) promoters to suppress their expression [57–59]. Despite these promising findings, this study was limited to in vitro experiments, without in vivo animal model validation. To mitigate these limitations, future studies should analyze key apoptosis- and cell cycle-related markers such as caspase-3, Bax, Bcl-2, p53, and cyclins, particularly by validating lncRNAs modulation in large cohorts to evaluate interpatient variability. Additionally, exploring combinations with other drugs may improve treatment results. Conclusion In conclusion, our results demonstrate that lncRNAs CLMAT3 and ZNRD1-AS1 are upregulated in CRC tissues and act as oncogenes, although they appear unsuitable as standalone diagnostic biomarkers. The upregulation of CLMAT3 showed a significant correlation with lymph node metastasis in patients. Furthermore, DOX encapsulated within CS/Au NPs markedly improved therapeutic efficacy in HCT116 cells, showing no significant cytotoxicity in HFFF2 cells, and has a higher uptake rate in HCT116 cells. CS/Au-DOX NPs promote apoptosis, induce G2/M arrest, inhibit migration, and downregulate CLMAT3 and ZNRD1-AS1 expression, supporting their promise as a targeted nanoformulation for CRC therapy. These findings suggest that although CLMAT3 and ZNRD1-AS1 may have limited diagnostic value, they could represent candidate therapeutic targets or treatment-responsive molecular markers in CRC. Our findings suggest therapeutic potential, although further in vivo studies are required.